Theriva Total Cash From Financing Activities from 2010 to 2024

TOVX Stock  USD 1.34  0.06  4.69%   
Theriva Biologics Total Cash From Financing Activities yearly trend continues to be fairly stable with very little volatility. Total Cash From Financing Activities will likely drop to about 593.8 K in 2024. During the period from 2010 to 2024, Theriva Biologics Total Cash From Financing Activities regression line of annual values had significance of  0.96 and arithmetic mean of  16,839,917. View All Fundamentals
 
Total Cash From Financing Activities  
First Reported
1993-03-31
Previous Quarter
1.8 M
Current Value
3.7 M
Quarterly Volatility
10.2 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Theriva Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theriva Biologics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 101.5 K, Total Revenue of 0.0 or Other Operating Expenses of 13.9 M, as well as many indicators such as Price To Sales Ratio of 241, Dividend Yield of 0.0 or PTB Ratio of 0.17. Theriva financial statements analysis is a perfect complement when working with Theriva Biologics Valuation or Volatility modules.
  
Check out the analysis of Theriva Biologics Correlation against competitors.
For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide.

Latest Theriva Biologics' Total Cash From Financing Activities Growth Pattern

Below is the plot of the Total Cash From Financing Activities of Theriva Biologics over the last few years. It is Theriva Biologics' Total Cash From Financing Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Theriva Biologics' overall financial position and show how it may be relating to other accounts over time.
Total Cash From Financing Activities10 Years Trend
Very volatile
   Total Cash From Financing Activities   
       Timeline  

Theriva Total Cash From Financing Activities Regression Statistics

Arithmetic Mean16,839,917
Coefficient Of Variation119.94
Mean Deviation14,526,067
Median12,202,000
Standard Deviation20,197,798
Sample Variance408T
Range75.9M
R-Value(0.01)
Mean Square Error439.3T
R-Squared0.0002
Significance0.96
Slope(59,274)
Total Sum of Squares5711.3T

Theriva Total Cash From Financing Activities History

2024593.8 K
2023625 K
2022-1.9 M
202174 M
20193.4 M
201829.1 M
201718.5 M

About Theriva Biologics Financial Statements

Theriva Biologics investors use historical fundamental indicators, such as Theriva Biologics' Total Cash From Financing Activities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Theriva Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Cash From Financing Activities625 K593.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Theriva Stock Analysis

When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.